Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Includes thermostabilized Ebola vaccines
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Subscribe To Our Newsletter & Stay Updated
